Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Lannett Company, Inc.    LCI

News SummaryMost relevantAll newsSector newsTweets

Lannett Company, Inc. : Lannett Announces Preliminary Fiscal 2013 Third Quarter Net Sales of $39 Million, Earnings Per Share between $0.12 and $0.14

share with twitter share with LinkedIn share with facebook
share via e-mail
04/30/2013 | 10:10pm CEST

Company to Report Full Financial Results, Host Conference Call on Wednesday, May 8

Lannett Company, Inc. (NYSE MKT: LCI) today announced that it expects to report fiscal 2013 third quarter net sales of approximately $39 million and diluted earnings per share between $0.12 and $0.14. For the prior year third quarter, net sales were $30.7 million and diluted earnings per share were $0.06. The company said the improved performance was driven by strong sales of existing and new products, as well as solid gross margin due to favorable product mix and enhanced manufacturing efficiencies.

Lannett will report full financial results for its fiscal 2013 third quarter Wednesday, May 8, 2013 after the market closes and will host a conference call that same afternoon at 4:30 p.m. Eastern (1:30 p.m. Pacific) to review the company's performance and answer questions.

The conference call will be available to interested parties by dialing 877-261-8992 from the U.S. or Canada, or 847-619-6548 from international locations, passcode 34792521. The call will also be available through a live, listen-only audio broadcast via the Internet at www.lannett.com. Listeners are encouraged to visit the website at least 15 minutes prior to the start of the scheduled presentation to register, download and install any necessary audio software. A playback of the call will be archived and accessible on the same website for at least three months.

About Lannett Company, Inc.:

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. For more information, visit the company's website at www.lannett.com.

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statements, including, but not limited to, the reporting of its preliminary financial results, whether expressed or implied, are subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the difficulty in predicting the timing or outcome of FDA or other regulatory approvals or actions, the ability to successfully commercialize products upon approval, Lannett's estimated or anticipated future financial results, future inventory levels, future competition or pricing, future levels of operating expenses, product development efforts or performance, and other risk factors discussed in the company's Form 10-K and other documents filed with the Securities and Exchange Commission from time to time. These forward-looking statements represent the company's judgment as of the date of this news release. The company disclaims any intent or obligation to update these forward-looking statements.

PondelWilkinson Inc.
Roger Pondel, 310-279-5980

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on LANNETT COMPANY, INC.
08/09 LANNETT : Announces Preliminary Fiscal 2017 Fourth Quarter and Full Year Financi..
08/08 LANNETT : Announces Preliminary Fiscal 2017 Fourth-Quarter And Full-Year Financi..
08/01 LANNETT : To Present At The Canaccord Genuity 37th Annual Growth Conference On A..
07/19 LANNETT CO INC : Change in Directors or Principal Officers, Financial Statements..
07/18 LANNETT : Appoints Samuel H. Israel As General Counsel
07/17 LANNETT COMPANY, INC. : Corporate News Blog - Lannett Co. Receives Approval for ..
07/17 LANNETT : Appoints Samuel H. Israel As General Counsel
07/14 LANNETT : Receives Approval For Cyproheptadine Hydrochloride Syrup, 2 mg/5 mL
06/28 LANNETT COMPANY, INC. : Corporate News Blog - Lannett Receives Approval for Addi..
06/26 LANNETT : Receives Approval For Additional Dosage Strengths Of Hydrocodone Bitar..
More news
Financials ($)
Sales 2017 654 M
EBIT 2017 242 M
Net income 2017 10,2 M
Debt 2017 798 M
Yield 2017 -
P/E ratio 2017 417,33
P/E ratio 2018 12,65
EV / Sales 2017 2,11x
EV / Sales 2018 2,09x
Capitalization 583 M
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 26,2 $
Spread / Average Target 67%
EPS Revisions
Arthur P. Bedrosian Chief Executive Officer & Director
Jeffrey Farber Chairman
Martin P. Galvan CFO, Treasurer & Vice President-Finance
Robert Ehlinger Chief Information Officer & VP-logistics
Kristin A. Arnold Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.12%355 979
NOVARTIS7.69%216 915
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.59%194 554